Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy

NCT03244657 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Polypoid Choroidal Vasculopathy (PCV)

Interventions

DRUG: conbercept ophthalmic injection （0.5mg）
DRUG: conbercept ophthalmic injection （0.5mg）

Sponsor

Chengdu Kanghong Biotech Co., Ltd.